1
|
Pimolbutr K, Lim WT, Leeson R, Hopper C, Kalavrezos N, Liew C, Schilling C, Sinha D, Jay A, Agrawal R, Porter S, Fedele S. Prognosis of oral epithelial dysplasia in individuals with and without oral lichen planus. Oral Dis 2024; 30:504-517. [PMID: 36648368 DOI: 10.1111/odi.14503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Revised: 01/04/2023] [Accepted: 01/11/2023] [Indexed: 01/18/2023]
Abstract
OBJECTIVES To investigate the role of oral lichen planus (OLP) on the long-term prognosis of oral epithelial dysplasia (OED). METHODS Retrospective single-centre cohort study using the 2007-2019 database of the Head and Neck Cancer and Oral Medicine units of University College London Hospital. The exposure of interest was the presence of OLP, and the prognostic outcomes included the development of new primary episodes of OED, progression to malignancy and mortality. Cox proportional hazard and Poisson regression models were performed. RESULTS A total of 299 patients, of whom 144 had OED arising on the background of OLP (OLP/OED) and 155 had OED without underlying OLP (non-OLP/OED), were included. A pre-existing diagnosis of OLP was significantly associated with a twofold increased risk of subsequent primary OED events (HR = 2.02, p = 0.04), which also developed faster (1.46 vs. 2.96 years, p = 0.04) and with more involvement of non-cancer-prone sites (p = 0.001) than in the non-OLP/OED group. There was no difference between groups in the progression to malignancy or mortality. CONCLUSIONS Oral lichen planus/OED patients are at higher risk of multiple episodes of primary OED, which can develop faster and at non-cancer-prone sites as compared to non-OLP/OED individuals. Further research is needed to clarify the effects of OLP upon progression to OSCC and mortality.
Collapse
Affiliation(s)
- Kununya Pimolbutr
- UCL Eastman Dental Institute, University College London, London, UK
- Department of Oral Medicine and Periodontology, Faculty of Dentistry, Mahidol University, Bangkok, Thailand
| | - Woei Tatt Lim
- Oral and Maxillofacial Surgery Department, Sarawak General Hospital, Kuching, Malaysia
| | - Rachel Leeson
- UCL Eastman Dental Institute, University College London, London, UK
| | - Colin Hopper
- UCL Eastman Dental Institute, University College London, London, UK
| | - Nicholas Kalavrezos
- Head and Neck Surgery Department, University College London Hospitals (UCLH), London, UK
| | - Colin Liew
- Head and Neck Surgery Department, University College London Hospitals (UCLH), London, UK
| | - Clare Schilling
- Head and Neck Surgery Department, University College London Hospitals (UCLH), London, UK
| | - Deepti Sinha
- Head and Neck Surgery Department, University College London Hospitals (UCLH), London, UK
| | - Amrita Jay
- Department of Cellular Pathology, University College London Hospitals (UCLH), London, UK
| | - Reshma Agrawal
- Department of Cellular Pathology, University College London Hospitals (UCLH), London, UK
| | - Stephen Porter
- UCL Eastman Dental Institute, University College London, London, UK
- NIHR UCLH Biomedical Research Centre, London, UK
| | - Stefano Fedele
- UCL Eastman Dental Institute, University College London, London, UK
- NIHR UCLH Biomedical Research Centre, London, UK
| |
Collapse
|
2
|
Turri-Zanoni M, Dalfino G, Lechner M, Dallan I, Battaglia P, Facco C, Franzi F, Gravante G, Ferrari M, Terzakis D, Jay A, Forster MD, Ambrosoli AL, Bignami M, Georgalas C, Herman P, Nicolai P, Lund VJ, Castelnuovo P. Biphenotypic sinonasal sarcoma: European multicentre case-series and systematic literature review. Acta Otorhinolaryngol Ital 2022; 42:545-553. [PMID: 36654521 PMCID: PMC9853106 DOI: 10.14639/0392-100x-n2087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/03/2022] [Accepted: 10/03/2022] [Indexed: 01/18/2023]
Abstract
Objective Biphenotypic sinonasal sarcoma (BSNS) is a rare low-grade cancer that was included from the 4th edition of WHO classification of head and neck tumours. The purpose of this study is to analyse clinical behaviour, pattern of recurrences and survival outcomes of this neoplasm. Methods Retrospective review of patients affected by BSNS who were treated via an endoscopic-assisted approach in 6 European tertiary-care referral hospitals. Cases of BSNS described in literature since 2012 to date were fully reviewed, according to PRISMA guidelines. Results A total of 15 patients were included. Seven patients were treated via an endoscopic endonasal approach, 4 with endoscopic transnasal craniectomy, and 4 via a cranio-endoscopic approach. Adjuvant treatment was delivered in 2 cases. After a mean follow-up of 27.3 months, systemic metastasis was observed in 1 case; the 5-year overall survival and disease-free survival rates were 100% and 80 ± 17.9%, respectively. Conclusions BSNS is a locally aggressive tumour with a low recurrence rate and encouraging survival outcomes if properly treated with surgical resection and free margins followed by adjuvant radiotherapy for selected cases. Endoscopic-assisted surgery is safe and effective as an upfront treatment within a multidisciplinary care protocol.
Collapse
Affiliation(s)
- Mario Turri-Zanoni
- Division of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy, Head and Neck Surgery & Forensic Dissection Research center (HNS&FDRc), Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy
| | - Gianluca Dalfino
- Division of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy,Correspondence Gianluca Dalfino Division of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, via Guicciardini, 9, 21100 Varese, Italy Tel. +39 0332 278426. Fax +39 0332 278945 E-mail:
| | - Matt Lechner
- UCL Cancer Institute, University College London; Head and Neck Centre, University College London Hospitals and Barts Health NHS Trust, London, UK
| | - Iacopo Dallan
- ENT Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
| | - Paolo Battaglia
- Division of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy, Head and Neck Surgery & Forensic Dissection Research center (HNS&FDRc), Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy
| | - Carla Facco
- Department of Pathology, ASST Sette Laghi, University of Insubria, Varese, Italy
| | - Francesca Franzi
- Department of Pathology, ASST Sette Laghi, University of Insubria, Varese, Italy
| | - Giacomo Gravante
- Division of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy
| | - Marco Ferrari
- Section of Otorhinolaryngology-Head and Neck Surgery, Department of Neurosciences, University of Padua, Azienda Ospedaliera di Padova, Padua, Italy
| | - Dimitrios Terzakis
- Department of Otorhinolaryngology-Head & Neck Surgery, Hygeia Hospital, Athens, Greece
| | - Amrita Jay
- Department of Cellular Pathology, University College London Hospitals NHS Foundation Trust, London, UK
| | - Martin D. Forster
- UCL Cancer Institute, London, United Kingdom; Department of Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
| | - Andrea Luigi Ambrosoli
- Department of Anesthesia and Intensive Care, Filippo Del Ponte Hospital, ASST Sette Laghi, Varese, Italy
| | - Maurizio Bignami
- Head and Neck Surgery & Forensic Dissection Research center (HNS&FDRc), Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy, Department of Otolaryngology Head and Neck Surgery, University of Insubria, Como, Italy
| | - Christos Georgalas
- Department of Otorhinolaryngology-Head & Neck Surgery, Hygeia Hospital, Athens, Greece
| | - Philippe Herman
- Department of Otolaryngology, Lariboisière University Hospital, Paris Diderot University, APHP, Paris Sorbonne Cité, Paris, France
| | - Piero Nicolai
- Section of Otorhinolaryngology-Head and Neck Surgery, Department of Neurosciences, University of Padua, Azienda Ospedaliera di Padova, Padua, Italy
| | - Valerie J. Lund
- Royal National Throat, Nose and Ear Hospital, UCLH Foundation Trust, London, United Kingdom
| | - Paolo Castelnuovo
- Division of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy, Head and Neck Surgery & Forensic Dissection Research center (HNS&FDRc), Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy
| |
Collapse
|
3
|
Lechner M, Takahashi Y, Turri-Zanoni M, Ferrari M, Liu J, Counsell N, Mattavelli D, Rampinelli V, Vermi W, Lombardi D, Saade R, Park KW, Schartinger VH, Franchi A, Facco C, Sessa F, Battocchio S, Fenton TR, Vaz FM, O'Flynn P, Howard D, Stimpson P, Wang S, Hannan SA, Unadkat S, Hughes J, Dwivedi R, Forde CT, Randhawa P, Gane S, Joseph J, Andrews PJ, Dave M, Fleming JC, Thomson D, Zhu T, Teschendorff A, Royle G, Steele C, Jimenez JE, Laco J, Wang EW, Snyderman C, Lacy PD, Woods R, O'Neill JP, Saraswathula A, Kaur RP, Zhao T, Ramanathan M, Gallia GL, London NR, Le QT, West RB, Patel ZM, Nayak JV, Hwang PH, Hermsen M, Llorente J, Facchetti F, Nicolai P, Bossi P, Castelnuovo P, Jay A, Carnell D, Forster MD, Bell DM, Lund VJ, Hanna EY. International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System. J Neurol Surg B Skull Base 2022. [DOI: 10.1055/s-0042-1750178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
Abstract
Abstract
Objectives Sinonasal mucosal melanoma (SNMM) is an extremely rare and challenging sinonasal malignancy with a poor prognosis. Standard treatment involves complete surgical resection, but the role of adjuvant therapy remains unclear. Crucially, our understanding of its clinical presentation, course, and optimal treatment remains limited, and few advancements in improving its management have been made in the recent past.
Methods We conducted an international multicenter retrospective analysis of 505 SNMM cases from 11 institutions across the United States, United Kingdom, Ireland, and continental Europe. Data on clinical presentation, diagnosis, treatment, and clinical outcomes were assessed.
Results One-, three-, and five-year recurrence-free and overall survival were 61.4, 30.6, and 22.0%, and 77.6, 49.2, and 38.3%, respectively. Compared with disease confined to the nasal cavity, sinus involvement confers significantly worse survival; based on this, further stratifying the T3 stage was highly prognostic (p < 0.001) with implications for a potential modification to the current TNM staging system. There was a statistically significant survival benefit for patients who received adjuvant radiotherapy, compared with those who underwent surgery alone (hazard ratio [HR] = 0.74, 95% confidence interval [CI]: 0.57–0.96, p = 0.021). Immune checkpoint blockade for the management of recurrent or persistent disease, with or without distant metastasis, conferred longer survival (HR = 0.50, 95% CI: 0.25–1.00, p = 0.036).
Conclusions We present findings from the largest cohort of SNMM reported to date. We demonstrate the potential utility of further stratifying the T3 stage by sinus involvement and present promising data on the benefit of immune checkpoint inhibitors for recurrent, persistent, or metastatic disease with implications for future clinical trials in this field.
Collapse
Affiliation(s)
- Matt Lechner
- UCL Cancer Institute, University College London, London, United Kingdom
- UCL Division of Surgery and Interventional Science, University College London, London, United Kingdom
- Department of ENT, Barts Health NHS Trust, London, United Kingdom
| | - Yoko Takahashi
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
| | - Mario Turri-Zanoni
- Unit of Otorhinolaryngology—Head and Neck Surgery, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy
| | - Marco Ferrari
- Section of Otorhinolaryngology—Head and Neck Surgery, Department of Neurosciences, University of Padova, Padova, Italy
| | - Jacklyn Liu
- UCL Cancer Institute, University College London, London, United Kingdom
| | - Nicholas Counsell
- Cancer Research UK and UCL Cancer Trials Centre, University College London, London, United Kingdom
| | - Davide Mattavelli
- Unit of Otorhinolaryngology—Head and Neck Surgery, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy
| | - Vittorio Rampinelli
- Unit of Otorhinolaryngology—Head and Neck Surgery, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy
| | - William Vermi
- Unit of Otorhinolaryngology—Head and Neck Surgery, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy
| | - Davide Lombardi
- Unit of Otorhinolaryngology—Head and Neck Surgery, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy
| | - Rami Saade
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Department of Otolaryngology—Head and Neck Surgery, Lebanese American University, Beirut, Lebanon
| | - Ki Wan Park
- Rhinology and Endoscopic Skull Base Surgery, Department of Otolaryngology—Head and Neck Surgery, Stanford University School of Medicine, Palo Alto, California, United States
| | - Volker H. Schartinger
- Department of Otorhinolaryngology, Medical University of Innsbruck, Innsbruck, Austria
| | | | - Carla Facco
- Unit of Pathology, ASST Sette Laghi, University of Insubria, Varese, Italy
| | - Fausto Sessa
- Unit of Pathology, ASST Sette Laghi, University of Insubria, Varese, Italy
| | - Simonetta Battocchio
- Pathology Unit, Department of Molecular and Translational Medicine, University of Brescia, ASST Spedali Civili, Brescia, Italy
| | - Tim R. Fenton
- Cancer Sciences Unit, Faculty of Medicine, University of Southampton, United Kingdom
| | - Francis M. Vaz
- Royal National ENT Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, United Kingdom
| | - Paul O'Flynn
- Royal National ENT Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, United Kingdom
| | - David Howard
- Royal National ENT Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, United Kingdom
| | - Paul Stimpson
- Royal National ENT Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, United Kingdom
| | - Simon Wang
- Department of Oncology, Haematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Tumorzentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - S. Alam Hannan
- Royal National ENT Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, United Kingdom
| | - Samit Unadkat
- Royal National ENT Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, United Kingdom
| | - Jonathan Hughes
- Head and Neck Centre, University College London Hospitals NHS Trust, London, United Kingdom
| | - Raghav Dwivedi
- Head and Neck Centre, University College London Hospitals NHS Trust, London, United Kingdom
| | - Cillian T. Forde
- Royal National ENT Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, United Kingdom
| | - Premjit Randhawa
- Royal National ENT Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, United Kingdom
| | - Simon Gane
- Royal National ENT Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, United Kingdom
| | - Jonathan Joseph
- Royal National ENT Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, United Kingdom
| | - Peter J. Andrews
- Royal National ENT Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, United Kingdom
| | - Manas Dave
- Division of Dentistry, University of Manchester, Manchester, United Kingdom
| | - Jason C. Fleming
- Liverpool Head & Neck Centre, University of Liverpool, Liverpool, United Kingdom
| | - David Thomson
- Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom
- Liverpool Head & Neck Centre, University of Liverpool, Liverpool, United Kingdom
| | - Tianyu Zhu
- CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Shanghai, People's Republic of China
| | - Andrew Teschendorff
- CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Shanghai, People's Republic of China
| | - Gary Royle
- UCL Cancer Institute, University College London, London, United Kingdom
| | | | - Joaquin E. Jimenez
- Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, United States
| | - Jan Laco
- The Fingerland Department of Pathology, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Czech Republic
| | - Eric W. Wang
- Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, United States
- Center for Cranial Base Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
| | - Carl Snyderman
- Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, United States
- Center for Cranial Base Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
| | - Peter D. Lacy
- Department of Otolaryngology—Head and Neck Surgery, Beaumont Hospital, Dublin, Ireland
| | - Robbie Woods
- Department of Otolaryngology—Head and Neck Surgery, Beaumont Hospital, Dublin, Ireland
| | - James P. O'Neill
- Department of Otolaryngology—Head and Neck Surgery, Beaumont Hospital, Dublin, Ireland
- The Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Anirudh Saraswathula
- Department of Otolaryngology—Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, United States
| | - Raman Preet Kaur
- Department of Otolaryngology—Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, United States
| | - Tianna Zhao
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
| | - Murugappan Ramanathan
- Department of Otolaryngology—Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, United States
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
| | - Gary L. Gallia
- Department of Otolaryngology—Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, United States
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
| | - Nyall R. London
- Department of Otolaryngology—Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, United States
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
- Sinonasal and Skull Base Tumor Program—Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, United States
| | - Quynh-Thu Le
- Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California, United States
| | - Robert B. West
- Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California, United States
| | - Zara M. Patel
- Rhinology and Endoscopic Skull Base Surgery, Department of Otolaryngology—Head and Neck Surgery, Stanford University School of Medicine, Palo Alto, California, United States
| | - Jayakar V. Nayak
- Rhinology and Endoscopic Skull Base Surgery, Department of Otolaryngology—Head and Neck Surgery, Stanford University School of Medicine, Palo Alto, California, United States
| | - Peter H. Hwang
- Rhinology and Endoscopic Skull Base Surgery, Department of Otolaryngology—Head and Neck Surgery, Stanford University School of Medicine, Palo Alto, California, United States
| | - Mario Hermsen
- Department of Head and Neck Oncology, Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain
| | - Jose Llorente
- Department of Head and Neck Oncology, Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain
| | - Fabio Facchetti
- Pathology Unit, Department of Molecular and Translational Medicine, University of Brescia, ASST Spedali Civili, Brescia, Italy
| | - Piero Nicolai
- Section of Otorhinolaryngology—Head and Neck Surgery, Department of Neurosciences, University of Padova, Padova, Italy
| | - Paolo Bossi
- Medical Oncology, Department of Medical and Surgical Specialities, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy
| | - Paolo Castelnuovo
- Unit of Otorhinolaryngology—Head and Neck Surgery, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy
| | - Amrita Jay
- Department of Histopathology, University College London Hospitals NHS Trust, London, United Kingdom
| | - Dawn Carnell
- Head and Neck Centre, University College London Hospitals NHS Trust, London, United Kingdom
| | - Martin D. Forster
- UCL Cancer Institute, University College London, London, United Kingdom
| | - Diana M. Bell
- Disease Team Alignment: Head and Neck, City of Hope Medical Center, Duarte, California, United States
| | - Valerie J. Lund
- Royal National ENT Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, United Kingdom
| | - Ehab Y. Hanna
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
| |
Collapse
|
4
|
Lechner M, Takahashi Y, Turri-Zanoni M, Liu J, Counsell N, Hermsen M, Kaur RP, Zhao T, Ramanathan M, Schartinger VH, Emanuel O, Helman S, Varghese J, Dudas J, Riechelmann H, Sprung S, Haybaeck J, Howard D, Engel NW, Stewart S, Brooks L, Pickles JC, Jacques TS, Fenton TR, Williams L, Vaz FM, O'Flynn P, Stimpson P, Wang S, Hannan SA, Unadkat S, Hughes J, Dwivedi R, Forde CT, Randhawa P, Gane S, Joseph J, Andrews PJ, Royle G, Franchi A, Maragliano R, Battocchio S, Bewicke-Copley H, Pipinikas C, Webster A, Thirlwell C, Ho D, Teschendorff A, Zhu T, Steele CD, Pillay N, Vanhaesebroeck B, Mohyeldin A, Fernandez-Miranda J, Park KW, Le QT, West RB, Saade R, Manes RP, Omay SB, Vining EM, Judson BL, Yarbrough WG, Sansovini M, Silvia N, Grassi I, Bongiovanni A, Capper D, Schüller U, Thavaraj S, Sandison A, Surda P, Hopkins C, Ferrari M, Mattavelli D, Rampinelli V, Facchetti F, Nicolai P, Bossi P, Henriquez OA, Magliocca K, Solares CA, Wise SK, Llorente JL, Patel ZM, Nayak JV, Hwang PH, Lacy PD, Woods R, O'Neill JP, Jay A, Carnell D, Forster MD, Ishii M, London NR, Bell DM, Gallia GL, Castelnuovo P, Severi S, Lund VJ, Hanna EY. Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. Eur J Cancer 2022; 162:221-236. [PMID: 34980502 PMCID: PMC9554673 DOI: 10.1016/j.ejca.2021.09.046] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2021] [Accepted: 09/28/2021] [Indexed: 02/03/2023]
Abstract
INTRODUCTION Olfactory neuroblastoma (ONB) is a rare cancer of the sinonasal region. We provide a comprehensive analysis of this malignancy with molecular and clinical trial data on a subset of our cohort to report on the potential efficacy of somatostatin receptor 2 (SSTR2)-targeting imaging and therapy. METHODS We conducted a retrospective analysis of 404 primary, locally recurrent, and metastatic olfactory neuroblastoma (ONB) patients from 12 institutions in the United States of America, United Kingdom and Europe. Clinicopathological characteristics and treatment approach were evaluated. SSTR2 expression, SSTR2-targeted imaging and the efficacy of peptide receptor radionuclide therapy [PRRT](177Lu-DOTATATE) were reported in a subset of our cohort (LUTHREE trial; NCT03454763). RESULTS Dural infiltration at presentation was a significant predictor of overall survival (OS) and disease-free survival (DFS) in primary cases (n = 278). Kadish-Morita staging and Dulguerov T-stage both had limitations regarding their prognostic value. Multivariable survival analysis demonstrated improved outcomes with lower stage and receipt of adjuvant radiotherapy. Prophylactic neck irradiation significantly reduces the rate of nodal recurrence. 82.4% of the cohort were positive for SSTR2; treatment of three metastatic cases with SSTR2-targeted peptide-radionuclide receptor therapy (PRRT) in the LUTHREE trial was well-tolerated and resulted in stable disease (SD). CONCLUSIONS This study presents pertinent clinical data from the largest dataset, to date, on ONB. We identify key prognostic markers and integrate these into an updated staging system, highlight the importance of adjuvant radiotherapy across all disease stages, the utility of prophylactic neck irradiation and the potential efficacy of targeting SSTR2 to manage disease.
Collapse
Affiliation(s)
- Matt Lechner
- UCL Cancer Institute, University College London, London, UK; Academic Head and Neck Centre, UCL Division of Surgery and Interventional Science, University College London, London, UK; ENT Department, Barts Health NHS Trust, London, United Kingdom; Rhinology & Endoscopic Skull Base Surgery, Department of Otolaryngology-H&N Surgery, Stanford University School of Medicine, Palo Alto, USA.
| | - Yoko Takahashi
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - Mario Turri-Zanoni
- Unit of Otorhinolaryngology and Head & Neck Surgery, Department of Biotechnology and Life Sciences, ASST Sette Laghi, University of Insubria, Varese, Italy
| | - Jacklyn Liu
- UCL Cancer Institute, University College London, London, UK
| | - Nicholas Counsell
- Cancer Research UK & UCL Cancer Trials Centre, University College London, London, UK
| | - Mario Hermsen
- Department of Head and Neck Oncology, Instituto de Investigacio´n Sanitaria Del Principado de Asturias (ISPA), Instituto Universitario de Oncologı´a Del Principado de Asturias (IUOPA), Centro de Investigacio´n Biome´dica en Red (CIBER-ONC), Oviedo, Spain
| | - Raman Preet Kaur
- Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, USA
| | - Tianna Zhao
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, USA
| | - Murugappan Ramanathan
- Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, USA
| | - Volker H Schartinger
- Department of Otorhinolaryngology, Medical University of Innsbruck, Innsbruck, Austria
| | - Oscar Emanuel
- UCL Cancer Institute, University College London, London, UK
| | - Sam Helman
- Department of Otolaryngology-Head and Neck Surgery, Emory University School of Medicine, Atlanta, USA
| | - Jordan Varghese
- Department of Otolaryngology-Head and Neck Surgery, Emory University School of Medicine, Atlanta, USA
| | - Jozsef Dudas
- Department of Otorhinolaryngology, Medical University of Innsbruck, Innsbruck, Austria
| | - Herbert Riechelmann
- Department of Otorhinolaryngology, Medical University of Innsbruck, Innsbruck, Austria
| | - Susanne Sprung
- Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria
| | - Johannes Haybaeck
- Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria; Diagnostic & Research Center for Molecular BioMedicine, Institute of Pathology, Medical University Graz, Graz, Austria
| | - David Howard
- Head and Neck Cancer Unit, Imperial College Healthcare NHS Trust, London, UK
| | - Nils Wolfgang Engel
- Department of Oncology, Haematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Tumorzentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Sarah Stewart
- Head and Neck Centre, University College London Hospitals NHS Trust, London, UK
| | - Laura Brooks
- Head and Neck Centre, University College London Hospitals NHS Trust, London, UK
| | - Jessica C Pickles
- Department of Developmental Biology and Cancer & Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK; Department of Histopathology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | - Thomas S Jacques
- Department of Developmental Biology and Cancer & Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK; Department of Histopathology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | - Tim R Fenton
- School of Biosciences, University of Kent, Canterbury, UK; School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
| | - Luke Williams
- UCL Division of Surgery and Interventional Science, University College London, London, UK
| | - Francis M Vaz
- Royal National Ear, Nose and Throat Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK
| | - Paul O'Flynn
- Royal National Ear, Nose and Throat Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK
| | - Paul Stimpson
- Royal National Ear, Nose and Throat Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK
| | - Simon Wang
- Institute of Nuclear Medicine, University College London, London, UK
| | - S Alam Hannan
- Royal National Ear, Nose and Throat Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK
| | - Samit Unadkat
- Royal National Ear, Nose and Throat Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK
| | - Jonathan Hughes
- Head and Neck Centre, University College London Hospitals NHS Trust, London, UK
| | - Raghav Dwivedi
- Head and Neck Centre, University College London Hospitals NHS Trust, London, UK
| | - Cillian T Forde
- Royal National Ear, Nose and Throat Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK
| | - Premjit Randhawa
- Royal National Ear, Nose and Throat Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK
| | - Simon Gane
- Royal National Ear, Nose and Throat Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK
| | - Jonathan Joseph
- Royal National Ear, Nose and Throat Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK
| | - Peter J Andrews
- Royal National Ear, Nose and Throat Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK
| | - Gary Royle
- UCL Cancer Institute, University College London, London, UK
| | | | - Roberta Maragliano
- Department of Medicine and Surgery, Unit of Pathology, University of Insubria, Varese, Italy
| | - Simonetta Battocchio
- Pathology Unit, Department of Molecular and Translational Medicine, University of Brescia, ASST Spedali Civili, Brescia, Italy
| | | | | | - Amy Webster
- UCL Cancer Institute, University College London, London, UK
| | - Chrissie Thirlwell
- UCL Cancer Institute, University College London, London, UK; College of Medicine and Health and Institute of Biomedical and Clinical Science, University of Exeter, Exeter, UK
| | - Debbie Ho
- Stem Cell Institute, University of Cambridge, Cambridge, UK
| | - Andrew Teschendorff
- CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Shanghai, China
| | - Tianyu Zhu
- CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Shanghai, China
| | - Christopher D Steele
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, USA
| | | | | | - Ahmed Mohyeldin
- Department of Neurosurgery, Stanford University School of Medicine, Palo Alto, USA
| | | | - Ki Wan Park
- Rhinology & Endoscopic Skull Base Surgery, Department of Otolaryngology-H&N Surgery, Stanford University School of Medicine, Palo Alto, USA
| | - Quynh-Thu Le
- Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, USA
| | - Robert B West
- Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, USA
| | - Rami Saade
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - R Peter Manes
- Department of Neurosurgery, Yale School of Medicine, New Haven, USA
| | | | - Eugenia M Vining
- Department of Neurosurgery, Yale School of Medicine, New Haven, USA
| | | | - Wendell G Yarbrough
- Department of Otolaryngology/Head and Neck Surgery, UNC School of Medicine, Chapel Hill, NC, USA
| | - Maddalena Sansovini
- Therapeutic Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Nicolini Silvia
- Therapeutic Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Ilaria Grassi
- Therapeutic Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Alberto Bongiovanni
- Osteoncology and Rare Tumors Center (CDO-TR), IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - David Capper
- Department of Neuropathology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany; German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Ulrich Schüller
- Department of Pediatric Hematology and Oncology, Institute of Neuropathology, And Research Institute Children's Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Selvam Thavaraj
- Centre for Clinical, Oral & Translational Science, King's College London, Department of Head and Neck Pathology, Guy's Hospital, London, UK
| | - Ann Sandison
- Department of Head and Neck Pathology, Guy's Hospital, London, UK
| | | | | | - Marco Ferrari
- Section of Otorhinolaryngology - Head and Neck Surgery, Department of Neurosciences, University of Padova, Italy
| | - Davide Mattavelli
- Unit of Otorhinolaryngology - Head and Neck Surgery, Department of Medical and Surgical Specialities, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy
| | - Vittorio Rampinelli
- Unit of Otorhinolaryngology - Head and Neck Surgery, Department of Medical and Surgical Specialities, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy
| | - Fabio Facchetti
- Pathology Unit, Department of Molecular and Translational Medicine, University of Brescia, ASST Spedali Civili, Brescia, Italy
| | - Piero Nicolai
- Section of Otorhinolaryngology - Head and Neck Surgery, Department of Neurosciences, University of Padova, Italy
| | - Paolo Bossi
- Medical Oncology, Department of Medical and Surgical Specialities, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy
| | - Oswaldo A Henriquez
- Department of Otolaryngology-Head and Neck Surgery, Emory University School of Medicine, Atlanta, USA
| | - Kelly Magliocca
- Department of Pathology, Emory University School of Medicine, Atlanta, USA
| | - C Arturo Solares
- Department of Otolaryngology-Head and Neck Surgery, Emory University School of Medicine, Atlanta, USA
| | - Sarah K Wise
- Department of Otolaryngology-Head and Neck Surgery, Emory University School of Medicine, Atlanta, USA
| | - Jose L Llorente
- Dept Otolaryngology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - Zara M Patel
- Rhinology & Endoscopic Skull Base Surgery, Department of Otolaryngology-H&N Surgery, Stanford University School of Medicine, Palo Alto, USA
| | - Jayakar V Nayak
- Rhinology & Endoscopic Skull Base Surgery, Department of Otolaryngology-H&N Surgery, Stanford University School of Medicine, Palo Alto, USA
| | - Peter H Hwang
- Rhinology & Endoscopic Skull Base Surgery, Department of Otolaryngology-H&N Surgery, Stanford University School of Medicine, Palo Alto, USA
| | - Peter D Lacy
- Department of Otolaryngology, Head and Neck Surgery, Beaumont Hospital, Dublin, Ireland
| | - Robbie Woods
- Department of Otolaryngology, Head and Neck Surgery, Beaumont Hospital, Dublin, Ireland
| | - James P O'Neill
- Department of Otolaryngology, Head and Neck Surgery, Beaumont Hospital, Dublin, Ireland; The Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Amrita Jay
- Department of Histopathology, University College London Hospitals NHS Trust, London, UK
| | - Dawn Carnell
- Head and Neck Centre, University College London Hospitals NHS Trust, London, UK
| | - Martin D Forster
- UCL Cancer Institute, University College London, London, UK; Academic Head and Neck Centre, UCL Division of Surgery and Interventional Science, University College London, London, UK; Department of Oncology, Haematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Tumorzentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Masaru Ishii
- Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, USA
| | - Nyall R London
- Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, USA; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, USA; Sinonasal and Skull Base Tumor Program, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, USA
| | - Diana M Bell
- Department of Pathology, The University of Texas MD Anderson Cancer Center Houston, USA; Division of Anatomic Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA, United States
| | - Gary L Gallia
- Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, USA; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, USA
| | - Paolo Castelnuovo
- Unit of Otorhinolaryngology and Head & Neck Surgery, Department of Biotechnology and Life Sciences, ASST Sette Laghi, University of Insubria, Varese, Italy
| | - Stefano Severi
- Therapeutic Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Valerie J Lund
- Royal National Ear, Nose and Throat Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK.
| | - Ehab Y Hanna
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA.
| |
Collapse
|
5
|
Adegun OK, Agrawal R, Jay A. SALIVARY GLAND LESIONS WITH ONCOCYTIC CHANGE: A 20-YEAR RETROSPECTIVE EVALUATION. Oral Surg Oral Med Oral Pathol Oral Radiol 2021. [DOI: 10.1016/j.oooo.2021.03.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
6
|
Agrawal R, Jay A, Adegun O. ORAL VERRUCOUS LESIONS—A DIAGNOSTIC DILEMMA: A 10-YEAR INSTITUTIONAL EXPERIENCE AND LITERATURE REVIEW. Oral Surg Oral Med Oral Pathol Oral Radiol 2021. [DOI: 10.1016/j.oooo.2021.03.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
7
|
Jay A, Kalavrezos N, Sinha D, Adegun OK, Agrawal R. DIVERSE HISTOMORPHOLOGY OF OSTEOSARCOMA; ILLUSTRATION OF TWELVE CASES. Oral Surg Oral Med Oral Pathol Oral Radiol 2021. [DOI: 10.1016/j.oooo.2021.03.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
8
|
Adegun OK, Kanona H, Joseph J, Jay A. Hairy polyp of the nasal vestibule. BMJ Case Rep 2021; 14:14/6/e242554. [PMID: 34116996 DOI: 10.1136/bcr-2021-242554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Affiliation(s)
- Oluyori Kutulola Adegun
- Department of Cellular Pathology, University College London Hospitals NHS Foundation Trust, London, UK
| | - Hala Kanona
- Royal National ENT and Eastman Dental Hospitals, University College London Hospitals NHS Foundation Trust, London, UK
| | - Jonathan Joseph
- Royal National ENT and Eastman Dental Hospitals, University College London Hospitals NHS Foundation Trust, London, UK
| | - Amrita Jay
- Department of Cellular Pathology, University College London Hospitals NHS Foundation Trust, London, UK
| |
Collapse
|
9
|
Lechner M, Schartinger VH, Steele CD, Nei WL, Ooft ML, Schreiber LM, Pipinikas CP, Chung GTY, Chan YY, Wu F, To KF, Tsang CM, Pearce W, Morelli D, Philpott M, Masterson L, Nibhani R, Wells G, Bell CG, Koller J, Delecluse S, Yip YL, Liu J, Forde CT, Forster MD, Jay A, Dudás J, Krapp A, Wan S, Uprimny C, Sprung S, Haybaeck J, Fenton TR, Chester K, Thirlwell C, Royle G, Marafioti T, Gupta R, Indrasari SR, Herdini C, Slim MAM, Indrawati I, Sutton L, Fles R, Tan B, Yeong J, Jain A, Han S, Wang H, Loke KSH, He W, Xu R, Jin H, Cheng Z, Howard D, Hwang PH, Le QT, Tay JK, West RB, Tsao SW, Meyer T, Riechelmann H, Oppermann U, Delecluse HJ, Willems SM, Chua MLK, Busson P, Lo KW, Wollmann G, Pillay N, Vanhaesebroeck B, Lund VJ. Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. Nat Commun 2021; 12:117. [PMID: 33402692 PMCID: PMC7785735 DOI: 10.1038/s41467-020-20308-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2020] [Accepted: 11/17/2020] [Indexed: 12/13/2022] Open
Abstract
Nasopharyngeal cancer (NPC), endemic in Southeast Asia, lacks effective diagnostic and therapeutic strategies. Even in high-income countries the 5-year survival rate for stage IV NPC is less than 40%. Here we report high somatostatin receptor 2 (SSTR2) expression in multiple clinical cohorts comprising 402 primary, locally recurrent and metastatic NPCs. We show that SSTR2 expression is induced by the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) via the NF-κB pathway. Using cell-based and preclinical rodent models, we demonstrate the therapeutic potential of SSTR2 targeting using a cytotoxic drug conjugate, PEN-221, which is found to be superior to FDA-approved SSTR2-binding cytostatic agents. Furthermore, we reveal significant correlation of SSTR expression with increased rates of survival and report in vivo uptake of the SSTR2-binding 68Ga-DOTA-peptide radioconjugate in PET-CT scanning in a clinical trial of NPC patients (NCT03670342). These findings reveal a key role in EBV-associated NPC for SSTR2 in infection, imaging, targeted therapy and survival.
Collapse
MESH Headings
- Animals
- Female
- Humans
- Male
- Mice
- Antineoplastic Agents/pharmacology
- Cell Line, Tumor
- Epstein-Barr Virus Infections/drug therapy
- Epstein-Barr Virus Infections/genetics
- Epstein-Barr Virus Infections/mortality
- Epstein-Barr Virus Infections/virology
- Gene Expression Regulation, Neoplastic
- Herpesvirus 4, Human/drug effects
- Herpesvirus 4, Human/growth & development
- Herpesvirus 4, Human/pathogenicity
- Host-Pathogen Interactions/genetics
- Lymphatic Metastasis
- Mice, Nude
- Molecular Targeted Therapy
- Nasopharyngeal Carcinoma/drug therapy
- Nasopharyngeal Carcinoma/genetics
- Nasopharyngeal Carcinoma/mortality
- Nasopharyngeal Carcinoma/virology
- Nasopharyngeal Neoplasms/drug therapy
- Nasopharyngeal Neoplasms/genetics
- Nasopharyngeal Neoplasms/mortality
- Nasopharyngeal Neoplasms/virology
- Neoplasm Recurrence, Local/drug therapy
- Neoplasm Recurrence, Local/genetics
- Neoplasm Recurrence, Local/mortality
- Neoplasm Recurrence, Local/virology
- NF-kappa B/genetics
- NF-kappa B/metabolism
- Octreotide/pharmacology
- Positron Emission Tomography Computed Tomography
- Receptors, Somatostatin/antagonists & inhibitors
- Receptors, Somatostatin/genetics
- Receptors, Somatostatin/metabolism
- Signal Transduction
- Survival Analysis
- Viral Matrix Proteins/antagonists & inhibitors
- Viral Matrix Proteins/genetics
- Viral Matrix Proteins/metabolism
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
- Matt Lechner
- UCL Cancer Institute, University College London, London, UK.
- Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Palo Alto, CA, USA.
- Barts Health NHS Trust, London, UK.
- Royal National Throat, Nose and Ear Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK.
| | - Volker H Schartinger
- Department of Otorhinolaryngology, Medical University of Innsbruck, Innsbruck, Austria
| | | | - Wen Long Nei
- Divisions of Radiation Oncology and Medical Sciences, National Cancer Centre, Singapore, Singapore
- Oncology Academic Programme, Duke-NUS Medical School, Singapore, Singapore
| | - Marc Lucas Ooft
- King´s College Hospitals, NHS Foundation Trust, London, UK
- Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Liesa-Marie Schreiber
- Institute of Virology and Christian Doppler Laboratory for Viral Immunotherapy of Cancer, Medical University of Innsbruck, Innsbruck, Austria
| | | | - Grace Tin-Yun Chung
- Department of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China
| | - Yuk Yu Chan
- Department of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China
| | - Feng Wu
- Department of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China
| | - Ka-Fai To
- Department of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China
| | - Chi Man Tsang
- Department of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China
| | - Wayne Pearce
- UCL Cancer Institute, University College London, London, UK
| | | | | | - Liam Masterson
- Department of Otolaryngology, Addenbrooke's Hospital, Cambridge, UK
| | - Reshma Nibhani
- Botnar Research Centre, University of Oxford, Oxford, UK
| | - Graham Wells
- Botnar Research Centre, University of Oxford, Oxford, UK
| | - Christopher G Bell
- William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| | - Julia Koller
- Department of Otorhinolaryngology, Medical University of Innsbruck, Innsbruck, Austria
- Botnar Research Centre, University of Oxford, Oxford, UK
| | - Susanne Delecluse
- German Cancer Research Centre (DKFZ) and Inserm, Unit F100/U1074, Heidelberg, Germany
| | - Yim Ling Yip
- School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China
| | - Jacklyn Liu
- UCL Cancer Institute, University College London, London, UK
| | - Cillian T Forde
- Royal National Throat, Nose and Ear Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK
| | - Martin D Forster
- UCL Cancer Institute, University College London, London, UK
- Royal National Throat, Nose and Ear Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK
| | - Amrita Jay
- Department of Histopathology, University College London Hospitals NHS Trust, Euston Road, London, UK
| | - József Dudás
- Department of Otorhinolaryngology, Medical University of Innsbruck, Innsbruck, Austria
| | - Annika Krapp
- Department of Otorhinolaryngology, Medical University of Innsbruck, Innsbruck, Austria
| | - Simon Wan
- Institute of Nuclear Medicine, University College Hospital, Euston Road, London, UK
| | - Christian Uprimny
- Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria
| | - Susanne Sprung
- Department of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria
| | - Johannes Haybaeck
- Department of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria
- Diagnostic & Research Center for Molecular Biomedicine, Institute of Pathology, Medical University of Graz, Graz, Austria
| | - Tim R Fenton
- School of Biosciences, University of Kent, Canterbury, UK
| | - Kerry Chester
- UCL Cancer Institute, University College London, London, UK
| | - Christina Thirlwell
- UCL Cancer Institute, University College London, London, UK
- University of Exeter College of Medicine and Health, Exeter, UK
| | - Gary Royle
- UCL Cancer Institute, University College London, London, UK
| | | | - Rajeev Gupta
- UCL Cancer Institute, University College London, London, UK
| | - Sagung Rai Indrasari
- ENT Head and Neck Surgery Department, Universitas Gadjah Mada, Dr. Sardjito Hospital, Yogyakarta, Indonesia
| | - Camelia Herdini
- ENT Head and Neck Surgery Department, Universitas Gadjah Mada, Dr. Sardjito Hospital, Yogyakarta, Indonesia
| | - Mohd Afiq Mohd Slim
- Department of Ear, Nose and Throat, University Hospital Crosshouse, Crosshouse, Kilmarnock, UK
| | - I Indrawati
- Department of Anatomical Pathology, Universitas Gadjah Mada, Dr. Sardjito Hospital, Yogyakarta, Indonesia
| | | | - Renske Fles
- Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Bing Tan
- ENT Head and Neck Surgery Department, Universitas Gadjah Mada, Dr. Sardjito Hospital, Yogyakarta, Indonesia
- Department of ENT/Head and Neck Surgery, Maastricht University Medical Center (MUMC), Maastricht, The Netherlands
| | - Joe Yeong
- Department of Anatomical Pathology, Singapore General Hospital, Singapore, Singapore
- Institute of Molecular and Cell Biology, A*STAR, Singapore, Singapore
| | - Amit Jain
- Division of Medical Oncology, National Cancer Centre, Singapore, Singapore
| | - Shuting Han
- Division of Medical Oncology, National Cancer Centre, Singapore, Singapore
| | - Haitao Wang
- Divisions of Radiation Oncology and Medical Sciences, National Cancer Centre, Singapore, Singapore
| | - Kelvin S H Loke
- Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore, Singapore
| | - Wan He
- Department of Oncology, The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, Guangdong, China
| | - Ruilian Xu
- Department of Oncology, The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, Guangdong, China
| | - Hongtao Jin
- Department of Pathology, The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, Guangdong, China
| | - Zhiqiang Cheng
- Department of Pathology, The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, Guangdong, China
| | - David Howard
- Royal National Throat, Nose and Ear Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK
- ENT Department, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK
| | - Peter H Hwang
- Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Palo Alto, CA, USA
| | - Quynh-Thu Le
- Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, CA, USA
| | - Joshua K Tay
- Department of Pathology, Stanford University School of Medicine, Palo Alto, CA, USA
- Department of Otolaryngology-Head and Neck Surgery, National University of Singapore, Singapore, Singapore
| | - Robert B West
- Department of Pathology, Stanford University School of Medicine, Palo Alto, CA, USA
| | - Sai Wah Tsao
- School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China
| | - Tim Meyer
- UCL Cancer Institute, University College London, London, UK
| | - Herbert Riechelmann
- Department of Otorhinolaryngology, Medical University of Innsbruck, Innsbruck, Austria
| | - Udo Oppermann
- Botnar Research Centre, University of Oxford, Oxford, UK
- Freiburg Institute for Advanced Studies (FRIAS), University of Freiburg, 79085, Freiburg, Germany
| | | | - Stefan M Willems
- Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
- Department of Pathology, University Medical Center Groningen, Groningen, The Netherlands
| | - Melvin L K Chua
- Divisions of Radiation Oncology and Medical Sciences, National Cancer Centre, Singapore, Singapore
- Oncology Academic Programme, Duke-NUS Medical School, Singapore, Singapore
| | - Pierre Busson
- CNRS-UMR 9018-METSY, Gustave Roussy and Université Paris-Saclay, Villejuif, France
| | - Kwok Wai Lo
- Department of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China
| | - Guido Wollmann
- Institute of Virology and Christian Doppler Laboratory for Viral Immunotherapy of Cancer, Medical University of Innsbruck, Innsbruck, Austria
| | - Nischalan Pillay
- UCL Cancer Institute, University College London, London, UK
- Department of Cellular and Molecular Pathology, Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK
| | | | - Valerie J Lund
- UCL Cancer Institute, University College London, London, UK.
- Royal National Throat, Nose and Ear Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK.
| |
Collapse
|
10
|
O'Callaghan ME, Jay A, Kichenadasse G, Moretti KL. Androgen deprivation therapy in unlikely to be effective for treatment of COVID-19. Ann Oncol 2020; 31:1780-1782. [PMID: 33007381 PMCID: PMC7525325 DOI: 10.1016/j.annonc.2020.09.014] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Revised: 08/27/2020] [Accepted: 09/06/2020] [Indexed: 11/15/2022] Open
Affiliation(s)
- M E O'Callaghan
- Urology Unit, Flinders Medical Centre, Bedford Park, Australia; College of Medicine and Public Health, Flinders University, Bedford Park, Australia; The Freemasons Centre for Male Health and Wellbeing, Adelaide University, Adelaide.
| | - A Jay
- Urology Unit, Flinders Medical Centre, Bedford Park, Australia; College of Medicine and Public Health, Flinders University, Bedford Park, Australia
| | - G Kichenadasse
- College of Medicine and Public Health, Flinders University, Bedford Park, Australia; Medical Oncology Unit, Flinders Medical Centre, Bedford Park, Australia
| | - K L Moretti
- College of Medicine and Public Health, Flinders University, Bedford Park, Australia; The Freemasons Centre for Male Health and Wellbeing, Adelaide University, Adelaide; Urology Unit, The Queen Elizabeth Hospital, Woodville, Australia; The UniSA Allied Health & Human Performance, The University of South Australia, Adelaide; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
| |
Collapse
|
11
|
Abstract
A 70-year-old woman presented with a 10-month history of an irregular mass in the left lateral nape of her neck which had recently increased in size rapidly. Ultrasound-guided core needle biopsy was obtained, and the tumour was diagnosed as a well-differentiated squamous cell carcinoma. Further imaging studies failed to demonstrate additional malignant characteristics. In view of these findings, a wide local excision of the tumour was performed. Histopathological assessment of the resected tumour revealed a proliferating trichilemmal tumour with well-differentiated features and smooth invasion front. This article serves as an important reminder of the challenges associated with pathological evaluation of core needle biopsies of adnexal tumours. It emphasises the importance of clinical-radiological-pathological correlation preferably in a multidisciplinary team setting prior to agreeing on a definitive management plan.
Collapse
Affiliation(s)
- Oluyori Kutulola Adegun
- Head and Neck Pathology Unit, Histopathology, University College London Hospitals, NHS Foundation Trust, London, UK
| | - Simon Morley
- Radiology (Imaging), University College London Hospitals, NHS Foundation Trust, London, UK
| | - Nicholas Kalavrezos
- Head and Neck Cancer Centre, University College London Hospitals, NHS Foundation Trust, London, UK
| | - Amrita Jay
- Head and Neck Pathology Unit, Histopathology, University College London Hospitals, NHS Foundation Trust, London, UK
| |
Collapse
|
12
|
Lechner M, Chakravarthy AR, Walter V, Masterson L, Feber A, Jay A, Weinberger PM, McIndoe RA, Forde CT, Chester K, Kalavrezos N, O'Flynn P, Forster M, Jones TM, Vaz FM, Hayes DN, Fenton TR. Frequent HPV-independent p16/INK4A overexpression in head and neck cancer. Oral Oncol 2018; 83:32-37. [DOI: 10.1016/j.oraloncology.2018.06.006] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2018] [Revised: 05/13/2018] [Accepted: 06/04/2018] [Indexed: 10/14/2022]
|
13
|
Tzanidakis K, Kalavrezos N, Sadiq Z, Jay A, Morley S, Wheelan J. The first case of intraosseous liposarcoma of the mandible involving the condyle. Int J Oral Maxillofac Surg 2017. [DOI: 10.1016/j.ijom.2017.02.995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
14
|
Farook S, Jay A, Morley S, Kalavrezos N, Sadiq Z. Synchronous unilateral histologically different three parotid tumours. Int J Oral Maxillofac Surg 2017. [DOI: 10.1016/j.ijom.2017.02.957] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
15
|
Farook S, Moss C, Jay A, Simon, Morley, Kalavrezos N, Sadiq Z. Tumour dimension and depth in T1 tongue squamous cell carcinoma: intraoral ultrasound scan and histological comparison. Int J Oral Maxillofac Surg 2017. [DOI: 10.1016/j.ijom.2017.02.425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Vassiliou LV, Lalabekyan B, Jay A, Liew C, Whelan J, Newman L, Kalavrezos N. Head and neck sarcomas: A single institute series. Oral Oncol 2016; 65:16-22. [PMID: 28109463 DOI: 10.1016/j.oraloncology.2016.12.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2016] [Revised: 12/01/2016] [Accepted: 12/04/2016] [Indexed: 01/26/2023]
Abstract
BACKGROUND Sarcomas are tumours of mesenchymal origin, accounting for 1% of all malignancies. METHODS This is a retrospective analysis of 107 head and neck sarcoma cases, treated over a period of thirteen years. RESULTS Fifty-four patients had with craniofacial bone sarcomas (BSs) (male: 33; female: 21) with high grade osteosarcoma being the most predominant type. The soft tissue sarcomas (STS) (53 patients; male: 28, female: 25) were histologically diverse with rhabdomyosarcomas and myxofibrosarcomas being the predominant types. The majority of BSs were managed with neoadjuvant chemotherapy followed by surgery, whereas in STSs treatment included predominantly surgery followed by radiotherapy. Overall survival estimates were 79% at 2years and 64% at 5years (mean follow-up period was 48months). CONCLUSIONS The mesenchymal origin of sarcomas, the pattern of disease spread and the different extent of cancellous bone infiltration in contrast to epithelial tumours, dictate distinct principles for surgical clearance.
Collapse
Affiliation(s)
| | | | - Amrita Jay
- University College London Hospital (UCLH), London, UK
| | - Colin Liew
- University College London Hospital (UCLH), London, UK
| | - Jeremy Whelan
- University College London Hospital (UCLH), London, UK
| | | | | |
Collapse
|
17
|
Hamdoon Z, Jerjes W, McKenzie G, Jay A, Hopper C. Optical coherence tomography in the assessment of oral squamous cell carcinoma resection margins. Photodiagnosis Photodyn Ther 2016. [PMID: 26210067 DOI: 10.1016/j.pdpdt.2015.07.170] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Zaid Hamdoon
- Unit of Oral and Maxillofacial Surgery, UCL Eastman Dental Institute, London, UK; Head and Neck Centre, University College London Hospitals, London, UK.
| | | | | | - Amrita Jay
- Head and Neck Centre, University College London Hospitals, London, UK.
| | - Colin Hopper
- Unit of Oral and Maxillofacial Surgery, UCL Eastman Dental Institute, London, UK; Head and Neck Centre, University College London Hospitals, London, UK; UCL Department of Surgery, London, UK.
| |
Collapse
|
18
|
Mairembam P, Jay A, Beale T, Morley S, Vaz F, Kalavrezos N, Kocjan G. Salivary gland FNA cytology: role as a triage tool and an approach to pitfalls in cytomorphology. Cytopathology 2015; 27:91-6. [PMID: 25656853 DOI: 10.1111/cyt.12232] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/08/2014] [Indexed: 12/12/2022]
Abstract
OBJECTIVE To highlight the importance of salivary gland fine needle aspiration (FNA) cytology as a triage tool for surgery and to determine its sensitivity and specificity. To discuss the diagnostic pitfalls and potential role of ancillary techniques in diagnosis and prognosis. METHODS The study included a total of 920 cases of salivary gland FNAs received in the cytopathology department of University College London Hospital during December 2004 to December 2012. The cases with known histological outcomes were analysed to determine the sensitivity and specificity. RESULTS Surgery was carried out on 180 (19.6%) of 920 patients. Excluding nine with inadequate/non-diagnostic cytology, the sensitivity of FNA cytology for a malignant outcome was 89% (33/37) and the specificity was 97% (130/134). Diagnostic pitfalls are discussed with respect to eight FNAs with discrepant histology. Histological outcome was not available for 740 cases (80.4%): excluding 88 non-diagnostic FNAs, 324 (49.7%) had non-neoplastic diagnoses (not indicating surgery) and 328 (50.3%) had neoplastic diagnoses, which included recurrences/metastases of known tumours. Patients with other neoplasms on FNA were lost to follow-up and may have had surgery elsewhere. Cases with clinical concerns were discussed at weekly multidisciplinary meetings. CONCLUSION Salivary gland FNA is crucial in the distinction of non-neoplastic from neoplastic lesions, emphasizing the fact that FNA is an excellent triage tool for surgery. Salivary gland FNA has a high sensitivity and specificity. However, it is important to interpret the cytological diagnoses in the light of clinical findings and imaging. Diagnostic pitfalls are seen in a minority of cases and could potentially be overcome with the help of recently described diagnostic and prognostic markers.
Collapse
Affiliation(s)
- P Mairembam
- Department of Histopathology, University College London Hospital, London, UK
| | - A Jay
- Department of Histopathology, University College London Hospital, London, UK
| | - T Beale
- Department of Imaging, University College London Hospital, London, UK
| | - S Morley
- Department of Imaging, University College London Hospital, London, UK
| | - F Vaz
- Department of Surgery, University College London Hospital, London, UK
| | - N Kalavrezos
- Department of Surgery, University College London Hospital, London, UK
| | - G Kocjan
- Department of Histopathology, University College London Hospital, London, UK
| |
Collapse
|
19
|
Caley A, Evans M, Powell N, Paleri V, Tomkinson A, Urbano TG, Jay A, Robinson M, Thavaraj S. Multicentric human papillomavirus-associated head and neck squamous cell carcinoma. Head Neck 2015; 37:202-8. [PMID: 24375667 DOI: 10.1002/hed.23584] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/18/2013] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND The purpose of this study was to present the clinicopathological features of a series of patients with human papillomavirus (HPV)-associated head and neck second primary tumors. METHODS Patients with HPV-associated head and neck second primary tumors from 3 centers were identified. HPV infection was evaluated using p16 by immunohistochemistry (IHC), high-risk HPV DNA by in situ hybridization (ISH), and HPV genotyping by DNA polymerase chain reaction (PCR) enzyme immunoassay (EIA). RESULTS Eleven patients were identified: 5 with synchronous and 6 with metachronous HPV-positive second primary tumors, the latter demonstrating a mean time interval of 5 years. There were 13 second primary tumors: 11 oropharyngeal, 1 nasopharyngeal, and 1 floor of the mouth. Nine of 10 genotyped patients harbored HPV-16, and 1 patient had HPV-33 in 3 synchronous tumors. CONCLUSION HPV-associated second primary tumors may present as synchronous and/or metachronous lesions and can arise outside the oropharynx after prolonged intervals. Further work is necessary to identify patients at risk and to elucidate the mechanisms of HPV-associated head and neck second primary tumors.
Collapse
Affiliation(s)
- Andrew Caley
- Department of Clinical Oncology, Velindre Cancer Centre, Cardiff, United Kingdom
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Shepard M, Sukumar S, Wall A, Menon R, Hegarty A, Buchanan J, Jay A, Coleman H, Shah S, Kerr A, Hodgson T. OI0345 Oral squamous cell carcinoma and epithelial dysplasia in HIV-infected individuals. Oral Surg Oral Med Oral Pathol Oral Radiol 2014. [DOI: 10.1016/j.oooo.2014.01.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Abstract
BACKGROUND Tumours of the lacrimal drainage apparatus (LDA) are very rare, but can be life-threatening. Seventy percent of lacrimal sac tumours are of epithelial origin, and transitional cell tumours represent an interesting sub-group of these epithelial tumours. METHODS A retrospective review of cases of LDA transitional cell tumours co-managed at the Royal National Throat Nose and Ear Hospital and Moorfields Eye Hospital, London. RESULTS Twenty cases of transitional cell tumours of the LDA were identified, comprising 10 transitional cell papillomas (TCPs) and 10 transitional cell carcinomas (TCCs). All cases were resected through a modified lateral rhinotomy approach. Limited resection of orbital fat with preservation of orbital functions was required for 2 cases of TCC. Fractionated external beam radiotherapy was administered in 7 cases of TCC. The mean follow up was 80 months (range 11 months-16 years). Recurrences were detected in 4 cases, which were managed by further surgery. Two cases have been lost to follow-up, but the 18 other patients are currently alive and disease free. CONCLUSION A favourable outcome can be achieved with transitional cell tumours of the LDA when an optimum management plan is followed.
Collapse
|
22
|
Frezza AM, Beale T, Bomanji J, Jay A, Kalavrezos N, Dileo P, Whelan J, Strauss SJ. Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment? BMC Cancer 2014; 14:23. [PMID: 24422949 PMCID: PMC3904418 DOI: 10.1186/1471-2407-14-23] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2012] [Accepted: 01/06/2014] [Indexed: 11/25/2022] Open
Abstract
Background We evaluated the role of 18FDG PET/CT used to assess response to preoperative chemotherapy in patients with primary craniofacial bone sarcomas. Methods Fourteen patients with craniofacial bone sarcomas (13 osteosarcoma, 1 spindle cell sarcoma) were retrospectively evaluated. All patients received up to 6 cycles of preoperative chemotherapy followed by resection of the primary tumour. Response to treatment was assessed using MRI (RECIST criteria) and 18FDG PET/CT (EORTC guidelines), performed at least at baseline, after 2-4 cycles and pre-operatively. Results The median baseline 18FDG PET/CT SUV was 10.2 (range 0-41); in 2 patients no uptake was detected. The preoperative 18FDG PET/CT, compared with the baseline, demonstrated a partial metabolic response in 7 patients (59%), complete metabolic response in 2 (16%) and stable metabolic disease in 3 (25%). In contrast, only two patients achieved a RECIST response on MRI: 10 (83%) had stable disease. One patient underwent early resection due to clinical progression after an initial response to treatment. This was confirmed by PET (SUV from 21 to 42) but not on MRI. Twelve of 14 patients (86%) had <90% histological necrosis in the resected tumour. At a median follow-up 23 months, 11 patients (79%) remain disease free, two had metastatic progression (14%) and 1 a local relapse (7%). The median DFS was 17 months. For those patients who achieved a response to preoperative 18FDG PET/CT the median DFS was 19 months (range: 1-66) compared with 3 months (range: 3-13) in those who did not (p = 0.01). In contrast, the median disease free survival (DFS) did not differ according to histological response (19 versus 17 months, >90% versus <90% necrosis, p = 0.45) or resection margins (19 months for R0 versus 18 months for R1, p = 0.2). Conclusion 18FDG PET/CT is more reliable than standard imaging in evaluating response to neo-adjuvant chemotherapy in craniofacial bone sarcomas, changed management in one patient, and in this small series, correlated better with patient outcome than histological response and resection margins. These results warrant prospective validation in a larger cohort of patients.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Sandra J Strauss
- The London Sarcoma Service, University College London Hospital, London, England.
| |
Collapse
|
23
|
Eweiss AZ, Lund VJ, Jay A, Rose G. Transitional cell tumours of the lacrimal drainage apparatus. Rhinology 2013; 51:349-54. [PMID: 24260768 DOI: 10.4193/rhino13.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Tumours of the lacrimal drainage apparatus (LDA) are very rare, but can be life-threatening. Seventy percent of lacrimal sac tumours are of epithelial origin, and transitional cell tumours represent an interesting sub-group of these epithelial tumours. METHODS A retrospective review of cases of LDA transitional cell tumours co-managed at the Royal National Throat Nose and Ear Hospital and Moorfields Eye Hospital, London. RESULTS Twenty cases of transitional cell tumours of the LDA were identified, comprising 10 transitional cell papillomas (TCPs) and 10 transitional cell carcinomas (TCCs). All cases were resected through a modified lateral rhinotomy approach. Limited resection of orbital fat with preservation of orbital functions was required for 2 cases of TCC. Fractionated external beam radiotherapy was administered in 7 cases of TCC. The mean follow up was 80 months (range 11 months-16 years). Recurrences were detected in 4 cases, which were managed by further surgery. Two cases have been lost to follow-up, but the 18 other patients are currently alive and disease free. CONCLUSION A favourable outcome can be achieved with transitional cell tumours of the LDA when an optimum management plan is followed.
Collapse
|
24
|
Wilson GA, Lechner M, Köferle A, Caren H, Butcher LM, Feber A, Fenton T, Jay A, Boshoff C, Beck S. Integrated virus-host methylome analysis in head and neck squamous cell carcinoma. Epigenetics 2013; 8:953-61. [PMID: 23867721 PMCID: PMC3883772 DOI: 10.4161/epi.25614] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
One in six cancers worldwide is caused by infection and human papillomavirus (HPV) is one of the main culprits. To better understand the dynamics of HPV integration and its effect on both the viral and host methylomes, we conducted whole-genome DNA methylation analysis using MeDIP-seq of HPV+ and HPV- head and neck squamous cell carcinoma (HNSCC). We determined the viral subtype to be HPV-16 in all cases and show that HPV-16 integrates into the host genome at multiple random sites and that this process predominantly involves the transcriptional repressor gene (E2) in the viral genome. Comparative analysis identified 453 (FDR ≤ 0.01) differentially methylated regions (DMRs) in the HPV+ host methylome. Bioinformatics characterization of these DMRs confirmed the previously reported cadherin genes to be affected but also revealed new targets for HPV-mediated methylation changes at regions not covered by array-based platforms, including the recently identified super-enhancers.
Collapse
Affiliation(s)
- Gareth A Wilson
- Medical Genomics; UCL Cancer Institute; University College London; London, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Lechner M, Frampton GM, Fenton T, Feber A, Palmer G, Jay A, Pillay N, Forster M, Cronin MT, Lipson D, Miller VA, Brennan TA, Henderson S, Vaz F, O'Flynn P, Kalavrezos N, Yelensky R, Beck S, Stephens PJ, Boshoff C. Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. Genome Med 2013; 5:49. [PMID: 23718828 PMCID: PMC4064312 DOI: 10.1186/gm453] [Citation(s) in RCA: 168] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2013] [Revised: 04/15/2013] [Accepted: 05/29/2013] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Human papillomavirus positive (HPV+) head and neck squamous cell carcinoma (HNSCC) is an emerging disease, representing a distinct clinical and epidemiological entity. Understanding the genetic basis of this specific subtype of cancer could allow therapeutic targeting of affected pathways for a stratified medicine approach. METHODS Twenty HPV+ and 20 HPV- laser-capture microdissected oropharyngeal carcinomas were used for paired-end sequencing of hybrid-captured DNA, targeting 3,230 exons in 182 genes often mutated in cancer. Copy number alteration (CNA) profiling, Sequenom MassArray sequencing and immunohistochemistry were used to further validate findings. RESULTS HPV+ and HPV- oropharyngeal carcinomas cluster into two distinct subgroups. TP53 mutations are detected in 100% of HPV negative cases and abrogation of the G1/S checkpoint by CDKN2A/B deletion and/or CCND1 amplification occurs in the majority of HPV- tumors. CONCLUSION These findings strongly support a causal role for HPV, acting via p53 and RB pathway inhibition, in the pathogenesis of a subset of oropharyngeal cancers and suggest that studies of CDK inhibitors in HPV- disease may be warranted. Mutation and copy number alteration of PI3 kinase (PI3K) pathway components appears particularly prevalent in HPV+ tumors and assessment of these alterations may aid in the interpretation of current clinical trials of PI3K, AKT, and mTOR inhibitors in HNSCC.
Collapse
Affiliation(s)
- Matthias Lechner
- UCL Cancer Institute, University College London, 72 Huntley Street, London, WC1E 6BT, UK ; Head and Neck Centre, University College London Hospitals NHS Trust, Euston Road, London, NW1 2PG, UK
| | - Garrett M Frampton
- Foundation Medicine, One Kendall Square, Suite B3501, Cambridge, MA 02139, USA
| | - Tim Fenton
- UCL Cancer Institute, University College London, 72 Huntley Street, London, WC1E 6BT, UK
| | - Andrew Feber
- UCL Cancer Institute, University College London, 72 Huntley Street, London, WC1E 6BT, UK
| | - Gary Palmer
- Foundation Medicine, One Kendall Square, Suite B3501, Cambridge, MA 02139, USA
| | - Amrita Jay
- Department of Histopathology, University College London Hospitals NHS Trust, Rockefeller Building, University Street, London, WC1E 6JJ, UK
| | - Nischalan Pillay
- UCL Cancer Institute, University College London, 72 Huntley Street, London, WC1E 6BT, UK
| | - Martin Forster
- UCL Cancer Institute, University College London, 72 Huntley Street, London, WC1E 6BT, UK ; Head and Neck Centre, University College London Hospitals NHS Trust, Euston Road, London, NW1 2PG, UK
| | - Maureen T Cronin
- Foundation Medicine, One Kendall Square, Suite B3501, Cambridge, MA 02139, USA
| | - Doron Lipson
- Foundation Medicine, One Kendall Square, Suite B3501, Cambridge, MA 02139, USA
| | - Vincent A Miller
- Foundation Medicine, One Kendall Square, Suite B3501, Cambridge, MA 02139, USA
| | - Timothy A Brennan
- Foundation Medicine, One Kendall Square, Suite B3501, Cambridge, MA 02139, USA
| | - Stephen Henderson
- UCL Cancer Institute, University College London, 72 Huntley Street, London, WC1E 6BT, UK
| | - Francis Vaz
- Head and Neck Centre, University College London Hospitals NHS Trust, Euston Road, London, NW1 2PG, UK
| | - Paul O'Flynn
- Head and Neck Centre, University College London Hospitals NHS Trust, Euston Road, London, NW1 2PG, UK
| | - Nicholas Kalavrezos
- Head and Neck Centre, University College London Hospitals NHS Trust, Euston Road, London, NW1 2PG, UK
| | - Roman Yelensky
- Foundation Medicine, One Kendall Square, Suite B3501, Cambridge, MA 02139, USA
| | - Stephan Beck
- UCL Cancer Institute, University College London, 72 Huntley Street, London, WC1E 6BT, UK
| | - Philip J Stephens
- Foundation Medicine, One Kendall Square, Suite B3501, Cambridge, MA 02139, USA
| | - Chris Boshoff
- UCL Cancer Institute, University College London, 72 Huntley Street, London, WC1E 6BT, UK
| |
Collapse
|
26
|
Wong T, Kalavrezos N, Liew C, Jay A, Lalabekyan B, Morley S, Beale T. OP215. Oral Oncol 2013. [DOI: 10.1016/j.oraloncology.2013.03.224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
27
|
Hamdoon Z, Jerjes W, Upile T, McKenzie G, Jay A, Hopper C. Optical coherence tomography in the assessment of suspicious oral lesions: An immediate ex vivo study. Photodiagnosis Photodyn Ther 2013; 10:17-27. [DOI: 10.1016/j.pdpdt.2012.07.005] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2012] [Revised: 07/24/2012] [Accepted: 07/29/2012] [Indexed: 11/29/2022]
|
28
|
|
29
|
Desai P, Jay A, Wu C, Cauley JA, Manson J, Peters U, Agalliu I, Abdul-Hussein M, Bock C, Budrys N, Chlebowski R, Cote M, Lane D, Luo J, Martin L, Park H, Petrucelli N, Rosenberg CA, Thomas F, Wactawski-Wende J, Simon MS. Abstract PD03-09: Statins and breast cancer risk: A follow-up analysis of the Women's Health Initiative Cohort. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-pd03-09] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Statins (HMG CoA reductase inhibitors) are a class of cholesterol lowering drugs that affect many intracellular pathways and have implications for chemopreventive activity against cancer. Epidemiological data on statins and breast cancer risk are conflicting. We analyzed updated data from the Women's Health Initiative (WHI) to assess the relationship between statins and breast cancer risk.
Methods: This analysis included 154,587 post-menopausal women ages 50–79 years at baseline, in which 7,430 incident cases of invasive breast cancer were identified over an average of 10.8 (SD 3.3) years of follow-up. All cases of breast cancer were confirmed by review of medical records and pathology reports. Participants were asked to bring all current medications to their baseline visits and information on statin use was recorded. Statins were classified as lipophilic (lovastatin, simvastatin, fluvastatin) or hydrophilic (pravastatin and atorvastatin). Self and interviewer-administered questionnaires were used to collect information on other breast cancer risk factors. Cox proportional hazards regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs). Analyses investigated the association of any statin use as well as, type of statin (lipophilic vs. hydrophilic), statin potency, and duration of use with breast cancer. To evaluate the effect of change in statin use over time, statin use was examined as a time-dependent exposure using updated information on statin use gathered during follow-up visits. Separate analyses were conducted by hormone receptor and HER2neu status, other tumor characteristics and use of postmenopausal hormone therapy. All statistical tests were two-sided.
Results: Statins were used at baseline by 11,584 (7.5%) women in the cohort of whom 7,840 used lipophilic statins. The annualized rate of breast cancer was 0.42% among statin users and 0.42% among nonusers. The multivariable adjusted HR of breast cancer for statin users compared with non-users was 0.93 (95% C.I. 0.83–1.05), however for women using lipophilic statins the HR was 0.86 (95% CI, 0.74–1.00). Statin use for < 1 year was associated with a reduction in risk (HR 0.79, 95% C.I. 0.63–0.99) however there was no trend for overall duration of use. In the stratified analysis by tumor size, there was a marginal reduction in risk for tumors between 10 and 30 mm but not in smaller or larger tumors. There were no effect modifications by tumor stage, hormone receptor or HER2neu status, hormone therapy use, family history of breast cancer or body mass index. In the multivariable adjusted time-dependent model, the HR for simvastatin was 0.80 (95% CI, 0.64–0.99).
Conclusion: Simvastatin was associated with a reduced risk of invasive breast cancer, and as a class, lipophilic statins were associated with a marginal benefit. This provides further evidence for possible class differences in statins with regard to chemo-preventive effects in breast cancer.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr PD03-09.
Collapse
Affiliation(s)
- P Desai
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - A Jay
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - C Wu
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - JA Cauley
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - J Manson
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - U Peters
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - I Agalliu
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - M Abdul-Hussein
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - C Bock
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - N Budrys
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - R Chlebowski
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - M Cote
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - D Lane
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - J Luo
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - L Martin
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - H Park
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - N Petrucelli
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - CA Rosenberg
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - F Thomas
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - J Wactawski-Wende
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| | - MS Simon
- Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY
| |
Collapse
|
30
|
Hamdoon Z, Jerjes W, Al-Delayme R, McKenzie G, Jay A, Hopper C. Structural validation of oral mucosal tissue using optical coherence tomography. Head Neck Oncol 2012; 4:29. [PMID: 22673083 PMCID: PMC3414779 DOI: 10.1186/1758-3284-4-29] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/16/2012] [Accepted: 06/06/2012] [Indexed: 11/16/2022]
Abstract
Background Optical coherence tomography (OCT) is a non-invasive optical technology using near-infrared light to produce cross-sectional tissue images with lateral resolution. Objectives The overall aims of this study was to generate a bank of normative and pathological OCT data of the oral tissues to allow identification of cellular structures of normal and pathological processes with the aim to create a diagnostic algorithm which can be used in the early detection of oral disorders. Material and methods Seventy-three patients with 78 suspicious oral lesions were referred for further management to the UCLH Head and Neck Centre, London. The entire cohort had their lesions surgically biopsied (incisional or excisional). The immediate ex vivo phase involved scanning the specimens using optical coherence tomography. The specimens were then processed by a histopathologist. Five tissue structures were evaluated as part of this study, including: keratin cell layer, epithelial layer, basement membrane, lamina propria and other microanatomical structures. Two independent assessors (clinician and pathologist trained to use OCT) assessed the OCT images and were asked to comment on the cellular structures and changes involving the five tissue structures in non-blind fashion. Results Correct identification of the keratin cell layer and its structural changes was achieved in 87% of the cohort; for the epithelial layer it reached 93.5%, and 94% for the basement membrane. Microanatomical structures identification was 64% for blood vessels, 58% for salivary gland ducts and 89% for rete pegs. The agreement was “good” between the clinician and the pathologist. OCT was able to differential normal from pathological tissue and pathological tissue of different entities in this immediate ex vivo study. Unfortunately, OCT provided inadequate cellular and subcellular information to enable the grading of oral premalignant disorders. Conclusion This study enabled the creation of OCT bank of normal and pathological oral tissues. The pathological changes identified using OCT enabled differentiation between normal and pathological tissues, and identification of different tissue pathologies. Further studies are required to assess the accuracy of OCT in identification of various pathological processes involving the oral tissues.
Collapse
Affiliation(s)
- Zaid Hamdoon
- Department of Oral & Maxillofacial Surgery, Dental School, Mosul, Iraq.
| | | | | | | | | | | |
Collapse
|
31
|
Liew C, Vassiliou L, Lalabekyan B, Jay A, Beale T, Morley S, Kalavrezos N. Managing margins in hard tissue sarcomas of the mandible. Br J Oral Maxillofac Surg 2012. [DOI: 10.1016/j.bjoms.2012.04.205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
32
|
Abstract
Carcinoma cuniculatum (CC) is a rare, distinct clinico-pathological variant of squamous cell carcinoma (SCC) that is defined histologically by the characteristic infiltrative pattern of a deep, broad, and complex proliferation of stratified squamous epithelium with keratin cores and keratin-filled crypts. Herein, we present a case report of CC of the oral tongue and discuss its diagnosis, management, and outcome, as well as briefly review the world literature. To our knowledge, this is the first documented case of CC of the tongue to be reported in the English literature. We draw attention to its clinico-pathological features and highlight that awareness of this entity as a distinct variant of SCC facilitates its correct management.
Collapse
Affiliation(s)
- Selvam Thavaraj
- Oral Pathology, Department of Clinical and Diagnostic Sciences, King’s College London Dental Institute, Floor 28 Tower Wing, Great Maze Pond, London, SE1 9RT UK
| | - Alistair Cobb
- Head & Neck Centre, University College London Hospitals NHS Foundation Trust, 1st Floor East Wing, 250 Euston Road, London, NW1 2PG UK
| | - Nicholas Kalavrezos
- Head & Neck Centre, University College London Hospitals NHS Foundation Trust, 1st Floor East Wing, 250 Euston Road, London, NW1 2PG UK
| | - Timothy Beale
- Department of Radiology, University College Hospital, 235 Euston Road, London, NW1 2BU UK
| | - Donald Murray Walker
- Department of Histopathology, University College London Hospitals NHS Foundation Trust, Rockefeller Building, University Street, London, WC1E 6JJ UK
| | - Amrita Jay
- Department of Histopathology, University College London Hospitals NHS Foundation Trust, Rockefeller Building, University Street, London, WC1E 6JJ UK
| |
Collapse
|
33
|
Vassiliou LV, Lalabekyan B, Wheelan J, Liew C, Pirgousis P, Ketabchi A, Jay A, Kalavrezos N. Sarcomas of the head and neck: a 13-year retrospective experience of a UK Sarcoma Center. Br J Oral Maxillofac Surg 2011. [DOI: 10.1016/j.bjoms.2011.03.242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
34
|
Sultan A, Wang JW, Woodhams J, Jay A, Berg K, Hogset A, MacRobert A, Bown S, Hopper C. TPCS2a based bleomycin photochemical internalization in normal hamster cheek pouch. Photodiagnosis Photodyn Ther 2011. [DOI: 10.1016/j.pdpdt.2011.03.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
35
|
Hamdoon Z, Jerjes W, McKenzie G, Jay A, Hopper C. Assessment of tumour resection margins using optical coherence tomography. Head Neck Oncol 2010. [PMCID: PMC3007724 DOI: 10.1186/1758-3284-2-s1-o7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
36
|
Hamdoon Z, Jerjes W, McKenzie G, Jay A, Hopper C. Assessment of suspicious oral lesions using optical coherence tomography. Head Neck Oncol 2010. [PMCID: PMC3007723 DOI: 10.1186/1758-3284-2-s1-o6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
37
|
Hamdoon Z, Jerjes W, Upile T, McKenzie G, Jay A, Hopper C. P24 Tumour resection margins subjected to optical coherence tomography. Br J Oral Maxillofac Surg 2010. [DOI: 10.1016/s0266-4356(10)60115-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
38
|
Hamdoon Z, Jerjes W, Upile T, McKenzie G, Jay A, Hopper C. P23 Assessment of premalignant/malignant oral lesions using optical coherence tomography. Br J Oral Maxillofac Surg 2010. [DOI: 10.1016/s0266-4356(10)60114-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
39
|
Jerjes W, Upile T, Petrie A, Riskalla A, Hamdoon Z, Vourvachis M, Karavidas K, Jay A, Sandison A, Thomas GJ, Kalavrezos N, Hopper C. Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients. Head Neck Oncol 2010; 2:9. [PMID: 20406474 PMCID: PMC2882907 DOI: 10.1186/1758-3284-2-9] [Citation(s) in RCA: 201] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/05/2010] [Accepted: 04/20/2010] [Indexed: 01/08/2023]
Abstract
The incidence of oral squamous cell carcinoma remains high. Oral and oro-pharyngeal carcinomas are the sixth most common cancer in the world. Several clinicopathological parameters have been implicated in prognosis, recurrence and survival, following oral squamous cell carcinoma. In this retrospective analysis, clinicopathological parameters of 115 T1/T2 OSCC were studied and compared to recurrence and death from tumour-related causes. The study protocol was approved by the Joint UCL/UCLH committees of the ethics for human research. The patients' data was entered onto proformas, which were validated and checked by interval sampling. The fields included a range of clinical, operative and histopathological variables related to the status of the surgical margins. Data collection also included recurrence, cause of death, date of death and last clinic review. Causes of death were collated in 4 categories (1) death from locoregional spread, (2) death from distant metastasis, (3) death from bronchopulmonary pneumonia, and (4) death from any non-tumour event that lead to cardiorespiratory failure. The patients' population comprised 65 males and 50 females. Their mean age at the 1st diagnosis of OSCC was 61.7 years. Two-thirds of the patients were Caucasians. Primary sites were mainly identified in the tongue, floor of mouth (FOM), buccal mucosa and alveolus. Most of the identified OSCCs were low-risk (T1N0 and T2N0). All patients underwent primary resection ± neck dissection and reconstruction when necessary. Twenty-two patients needed adjuvant radiotherapy. Pathological analysis revealed that half of the patients had moderately differentiated OSCC. pTNM slightly differed from the cTNM and showed that 70.4% of the patients had low-risk OSCC. Tumour clearance was ultimately achieved in 107 patients. Follow-up resulted in a 3-year survival of 74.8% and a 5-year survival of 72.2%. Recurrence was identified in 23 males and 20 females. The mean age of 1st diagnosis of the recurrence group was 59.53 years. Most common oral sites included the lateral border of tongue and floor of mouth. Recurrence was associated with clinical N-stage disease. The surgical margins in this group was evaluated and found that 17 had non-cohesive invasion, 30 had dysplasia at margin, 21 had vascular invasion, 9 had nerve invasion and 3 had bony invasion. Severe dysplasia was present in 37 patients. Tumour clearance was achieved in only 8 patients. The mean depth of tumour invasion in the recurrence group was 7.6 mm. An interesting finding was that 5/11 patients who died of distant metastasis had their primary disease in the tongue. Nodal disease comparison showed that 8/10 patients who died of locoregional metastasis and 8/11 patients who died from distant metastasis had clinical nodal involvement. Comparing this to pathological nodal disease (pTNM) showed that 10/10 patients and 10/11 patients who died from locoregional and distant metastasis, respectively, had nodal disease. All patients who died from locoregional and distant metastasis were shown to have recurrence after the primary tumour resection. Squamous cell carcinoma of the oral cavity has a poor overall prognosis with a high tendency to recur at the primary site and extend to involve the cervical lymph nodes. Several clinicopathological parameters can be employed to assess outcome, recurrence and overall survival.
Collapse
|
40
|
Hamdoon Z, Jerjes W, Upile T, McKenzie G, Betz CS, Sandison A, Jay A, Hopper C. Immediate ex vivo optical coherence tomography of suspicious oral lesions. Br J Oral Maxillofac Surg 2009. [DOI: 10.1016/j.bjoms.2009.06.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
41
|
Jerjes W, Upile T, Conn B, Hamdoon Z, Betz CS, McKenzie G, Radhi H, Vourvachis M, El Maaytah M, Sandison A, Jay A, Hopper C. In vitro examination of suspicious oral lesions using optical coherence tomography. Br J Oral Maxillofac Surg 2009; 48:18-25. [PMID: 19726114 DOI: 10.1016/j.bjoms.2009.04.019] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/07/2009] [Indexed: 11/17/2022]
Abstract
We compared findings of optical coherence tomography (OCT) with histopathological results of suspicious oral lesions to assess the feasibility of using OCT to identify malignant tissue. Thirty-four oral lesions from 27 patients had swept-source frequency-domain OCT. Four variables were assessed (changes in keratin, epithelial, and sub-epithelial layers, and identification of the basement membrane) and from this we calculated whether or not there were architectural changes. These data were then compared with histopathological results. Two clinicians, who were unaware of the clinical and histopathological diagnoses, decided whether biopsy was necessary. The basement membrane was recognised in only 15 oral lesions. OCT could identify diseased areas but could not provide a diagnosis or differentiate between lesions. The two clinicians, who recommended biopsy agreed in all cases. This pilot study confirms the feasibility of using OCT to identify architectural changes in malignant tissues.
Collapse
Affiliation(s)
- Waseem Jerjes
- Head & Neck Centre, University College London Hospital, London, United Kingdom. waseem
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Affiliation(s)
- David James Baldwin
- Paediatric Dentistry, Dental Institute, The Royal London Hospital, New Road, Whitechapel, London E1 1BB, UK.
| | | | | | | |
Collapse
|
43
|
Jay A, Hutchison I, Piper K, Farthing PM, Richards PS. Synovial sarcoma presenting as a parotid mass: Case report and review of literature. Head Neck 2008; 30:1654-9. [DOI: 10.1002/hed.20822] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
44
|
Jerjes W, Upile T, Conn B, Betz C, Abbas S, Jay A, Jamil W, Vourvachis M, Radhi R, El Maaytah M, Hopper C. Oral leukoplakia and erythroplakia subjected to optical coherence tomography: preliminary results. Br J Oral Maxillofac Surg 2008. [DOI: 10.1016/j.bjoms.2008.07.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
45
|
Jay A, Piper K, Farthing PM, Carter J, Diwakar A. Low-grade myofibroblastic sarcoma of the tongue. ACTA ACUST UNITED AC 2007; 104:e52-8. [PMID: 17964473 DOI: 10.1016/j.tripleo.2007.06.004] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2006] [Revised: 06/03/2007] [Accepted: 06/04/2007] [Indexed: 10/22/2022]
Abstract
Low-grade myofibroblastic sarcoma is a neoplasm of atypical myofibroblasts with fibromatoseslike features and a predilection for head and neck sites, including the oral cavity. These lesions have only been characterized in the last 2 decades, and controversies in the concept of neoplastic myofibroblasts still exist. Lack of obvious cytological atypia may result in their being mistaken for reactive fascitislike lesions or fibromatosis and architectural similarities to fibrosarcoma or leiomyosarcoma may complicate the diagnostic process. This paper describes a spindle cell neoplasm in a 40-year-old man that was diagnosed 9 years ago as an unclassifiable myofibroblastic proliferation. The recurrent tumor, which presented 6 years following excision of the original tumor, was subsequently classified as a low-grade myofibroblastic sarcoma. The morphological, immunohistochemical, and electron microscopic features of this unusual sarcoma and the most likely differential diagnoses are discussed.
Collapse
Affiliation(s)
- Amrita Jay
- Department of Cellular Pathology, Royal London NHS Trust, London, England.
| | | | | | | | | |
Collapse
|
46
|
Jay A, Dhanda J, Chiodini PL, Woodrow CJ, Farthing PM, Evans J, Jager HR. Oral cysticercosis. Br J Oral Maxillofac Surg 2006; 45:331-4. [PMID: 16388881 DOI: 10.1016/j.bjoms.2005.09.014] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2004] [Accepted: 09/14/2005] [Indexed: 10/25/2022]
Abstract
Cysticercosis is the result of infection with the larval stage of the tapeworm, Taenia solium. The parasite may settle at any site in the body without causing symptoms, which arise almost exclusively from the involvement of brain or eye, and this may occur several years after infection. Cysticercosis is one of the leading causes of acquired epilepsy in Latin America, parts of Asia, and Africa. More cases are being reported in other countries as a result of immigration from endemic areas. Cysticercosis may cause cystic swellings or nodules in the mouth, and these may be the only evidence of the disease. We present a healthy patient who had multiple intraoral cystic swellings that were diagnosed as cysticercosis in a biopsy specimen. Subsequent investigations showed cysticerci in the brain.
Collapse
Affiliation(s)
- Amrita Jay
- Histopathology Department, Oral Pathology, St Bartholomew's Hospital, West Smithfield, London, UK.
| | | | | | | | | | | | | |
Collapse
|
47
|
Jay A. A personal response to: The Woman Who Walked Into Doors by Roddy Doyle. Med Humanit 2000; 26:58-59. [PMID: 23669586 DOI: 10.1136/mh.26.1.58] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Affiliation(s)
- A Jay
- General Practitioner, Llandysul, Ceredigion, Wales
| |
Collapse
|
48
|
|
49
|
Jay A, Kilby MD, Roberts E, Brackley K, Platt C, McHugo J, Davison EV. Prenatal diagnosis of mosaicism for partial trisomy 8: a case report including fetal pathology. Prenat Diagn 1999; 19:976-9. [PMID: 10521826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
A case of prenatally diagnosed partial trisomy 8 is described. The 'syndrome' is associated with skeletal and cardiac anomalies, as well as hepatic calcification. Differing proportions of 47,XY, +der(8) and 46 XY were present in the different fetal tissues sampled. The highest proportion of 47,XY,+der(8) cells was found in the placenta.
Collapse
Affiliation(s)
- A Jay
- Regional Cytogenetics Laboratory, Birmingham Women's Hospital, Edgbaston, Birmingham, B15 2TG, U.K
| | | | | | | | | | | | | |
Collapse
|
50
|
Stevens M, Patel H, Walters A, Burch K, Jay A, Dowling N, Mitchell CJ, Swann RA, Willis AT, Shanson DC. Comparison of Sentinel and Bactec blood culture systems. J Clin Pathol 1992; 45:815-8. [PMID: 1401215 PMCID: PMC495112 DOI: 10.1136/jcp.45.9.815] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
AIMS To evaluate the Sentinel automated blood culture system and to compare its performance with that of Bactec. METHODS The Sentinel blood culture system was evaluated in three centres. The performance of the system was assessed in comparison with the routine blood culture method used in these centres, the Bactec system. RESULTS Blood culture sets (n = 2180) consisting of Sentinel aerobic and anaerobic, and Bactec aerobic and anaerobic bottles yielded 218 (10%) clinically important isolates. One hundred and fifty five (71%) of the isolates were detected by both systems; 35 (16%) were detected by Sentinel only; and 28 (13%) by Bactec only. For the duration of the evaluation, the Sentinel system was deliberately configured so that it was impossible to detect positive results during the first 12 hours. The times to positivity after the first 12 hours were similar. Data gathered during and subsequent to the evaluation have been used by the manufacturer to refine the algorithm so that positive results can be detected at a minimum of 2.25 hours. CONCLUSIONS After a period of familiarization the Sentinel system was considered easy to use. Sentinel is a useful addition to the methods available for the detection of bacteria in blood cultures.
Collapse
Affiliation(s)
- M Stevens
- Department of Health Evaluation Unit, Royal Infirmary, Leicester
| | | | | | | | | | | | | | | | | | | |
Collapse
|